Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (351-360 of 436) with videos related to

Pageof 44
Sort By:
The Journal of Rheumatology|May 17, 2015
Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 WorkshopJason W Busse, Susan J Bartlett, Maxime Dougados, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
The Journal of Rheumatology|November 3, 2005
Fibromyalgia syndromePhilip J Mease, Daniel J Clauw, Lesley M Arnold, et al.
BMJ Open|March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
The Journal of Rheumatology|March 3, 2019
Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid ArthritisMaria A Lopez-Olivo, José B Negrón, Richard J Zogala, et al.
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|February 17, 2019
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT MethodologyLara J Maxwell, Dorcas E Beaton, Beverley J Shea, et al.
Arthritis Care & Research|October 12, 2020
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled TrialJessica A Walsh, Marina N Magrey, Xenofon Baraliakos, et al.
Pageof 44

Showing results (351-360 of 436) with videos related to

Sort By:
Pageof 44
The Journal of Rheumatology|May 17, 2015
Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 WorkshopJason W Busse, Susan J Bartlett, Maxime Dougados, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
The Journal of Rheumatology|November 3, 2005
Fibromyalgia syndromePhilip J Mease, Daniel J Clauw, Lesley M Arnold, et al.
BMJ Open|March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
The Journal of Rheumatology|March 3, 2019
Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid ArthritisMaria A Lopez-Olivo, José B Negrón, Richard J Zogala, et al.
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|February 17, 2019
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT MethodologyLara J Maxwell, Dorcas E Beaton, Beverley J Shea, et al.
Arthritis Care & Research|October 12, 2020
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled TrialJessica A Walsh, Marina N Magrey, Xenofon Baraliakos, et al.
Pageof 44